EC Number   |
Application |
Reference  |
|---|
   3.5.3.18 | more |
dimerization is not critical for the maintenance of the biological function of the protein |
652942 |
| 3.5.3.18 | medicine |
2-chloroacetamidine may potentially find wide applicability as a general pharmacophore, useful in delineating characteristics of the amidinotransferase superfamily |
664074 |
| 3.5.3.18 | medicine |
decreased DDAH-1 expression may cause accumulation of endogenous inhibitors of enothelial NO synthase, thereby contributing to endothelial dysfunction in the failing heart |
667155 |
| 3.5.3.18 | medicine |
endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (hydrolyzed by DDAH) is elevated in many patients and may contribute to the initiation and progression of their disease |
667159 |
| 3.5.3.18 | medicine |
expression and secretion of the vascular endothelial growth factor is not increased in DDAH1-transfected cells |
667355 |
| 3.5.3.18 | medicine |
DDAH activity and elevated endogenous asymmetric dimethylarginine is implicated in endothelial dysfunction exposed to glycosylated bovine serum albumin, aminoguanidine can protect endothelium against injury induced by glycosylated bovine serum albumin both in vitro and in vivo |
667365 |
| 3.5.3.18 | more |
DDAH1 plays an important role in development |
668120 |
| 3.5.3.18 | medicine |
protective effect of probucol on endothelium related to enhancement of DDAH activity |
668175 |
| 3.5.3.18 | medicine |
epoetin beta and darbepoetin alpha posttranslationally impair DDAH activity via increased oxidative stress, causing NG,NG-dimethyl-L-arginine as an important cardiovascular risk factor to accumulate and inhibit NO-synthesis |
669059 |
| 3.5.3.18 | medicine |
in vivo administration of DDAH inhibitors (2-amino-4-(NG-methyl-guanidino)butanoic acid and its analogues) increases plasma NG,NG-dimethyl-L-arginine levels, giving proof of concept that these can be used to probe the physiological effects of DDAH inhibition, with potential for pharmaceutical use of DDAH inhibitors in diseases where excess NO production is implicated |
669780 |
